Plasma

News Plasma

• Excellent early results in large OvPlex ovarian cancer biomarker study

  Stage 1 of HealthLinx Limited’smulti-centre, multi-site second study for OvPlex™ has returned excellent initial data for the two new biomarkers AGR2 and HTX010 being evaluated for accuracy in diagnosing ovarian cancer. To date, AGR2 and HTX010 data have been analysed in over 400 case and control sam more

• Researchers show how cells open 'doors' to release neurotransmitters

  Like opening a door to exit a room, cells in the body open up their outer membranes to release such chemicals as neurotransmitters and other hormones. Cornell researchers have shed new light on this lightning-quick, impossibly small-scale process, called exocytosis, by casting sharp focus on what h more

• A revolutionary breakthrough in terahertz remote sensing

  A major breakthrough in remote wave sensing by a team of Rensselaer Polytechnic Institute researchers opens the way for detecting hidden explosives, chemical, biological agents and illegal drugs from a distance of 20 meters. The new, all-optical system, using terahertz (THz) wave technology, has gr more

White papers Plasma

• Homogeneous IgG AlphaLISA® assay performed on BMG LABTECH's PHERAstar Plus
  

  Immunoglobulins or antibodies are proteins that are involved in the immune response. That makes them interesting drug targets. This application note shows the detection of the immunoglobulin IgG using an AlphaLISA® assay performed on BMG LABTECH's PHERAstar Plus. The AlphaLISA® technology utilizes oxygen to start a cascade of chemical reactions resulting in a luminescence signal at 615 nm. Sensitivity and Z´values obtained in different plate formats are presented. more

• High sensitive detection of follistatin by Imperacer®: an initial study on the way to analytical gene-doping tests
  

  For the understanding of interactions in the muscle-growth directing myostatin-pathway and therefore also for the establishment of high sensitive detection strategies for gene-doping, detailed studies of protein concentration levels in biological matrices and appropriate highly sensitive analytic techniques for quantitative monitoring of these biomarkers are required. In this work, the development of a high sensitive assay for follistatin based on the Imperacer® technology is described. The quantification limit in human serum was found at 60 pg/ml in only 6 µl sample volume. With this initial assay we demonstrate the first application in a set of analytical tests for a high sensitive myostatin pathway related profiling. more

Websites Plasma